Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159
DA-8159 is a selective inhibitor of PDE 5-catalyzed cGMP hydrolysis and the enhancement of a penile erection by DA- 8159 is mediated by the relaxation of the cavernosal smooth muscle by the NO-stimulated cG MP accumulation.
Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human gastric cancer (AGS) cells.
- Min-Jung Kim, Do-Hee Kim, H. Na, T. Oh, C. Shin, Young-Joon Surh Ph D Professor
- Biology, MedicineJournal of environmental pathology, toxicology…
The ability of eupatilin to induce apoptosis in human gastric cancer (AGS) cells is examined and its perturbation of the mitochondrial transmembrane potential (DeltaPsim) is verified.
Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice
It is demonstrated for the first time that pharmacological DPP4 inhibition by evogliptin directly causes fat loss in established obese mice, providing insight into the regulation of energy storage in WAT caused by DPP 4 inhibition.
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention
The results suggest that PAR-1622 is a selective partial activator of PPARγ and has excellent antihyperglycemic activities and a broad safety profile for fluid retention.
A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control
Results suggest that central CB1 receptors mediate anorectic response ofCB1-receptor antagonists and peripheral modulations, including SREBP-1 expression, are not major mechanisms in the antiobesity effects of CB1- receptor antagonists.
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
Compound 18, one of the derivatives with an oxime ether linker, was found to selectively transactivate PPARgamma and lower blood glucose in db/ db mice more than muraglitazar after oral treatment for 11 days.